PRTA [NASD]
Prothena Corporation plc
Index- P/E- EPS (ttm)-3.34 Insider Own5.28% Shs Outstand46.99M Perf Week6.19%
Market Cap3.09B Forward P/E- EPS next Y-3.94 Insider Trans-16.81% Shs Float45.59M Perf Month8.62%
Income-156.50M PEG- EPS next Q-0.41 Inst Own93.10% Short Float / Ratio4.89% / 2.66 Perf Quarter141.55%
Sales5.20M P/S593.62 EPS this Y149.60% Inst Trans-4.71% Short Interest2.23M Perf Half Y136.36%
Book/sh8.61 P/B7.55 EPS next Y-33.10% ROA-27.30% Target Price80.89 Perf Year30.86%
Cash/sh10.44 P/C6.23 EPS next 5Y-0.60% ROE-36.50% 52W Range21.06 - 66.47 Perf YTD31.58%
Dividend- P/FCF- EPS past 5Y18.10% ROI14.40% 52W High-2.21% Beta0.50
Dividend %- Quick Ratio10.40 Sales past 5Y185.60% Gross Margin- 52W Low208.64% ATR4.12
Employees82 Current Ratio10.40 Sales Q/Q-98.90% Oper. Margin- RSI (14)60.85 Volatility8.54% 6.72%
OptionableYes Debt/Eq0.00 EPS Q/Q-145.70% Profit Margin- Rel Volume0.83 Prev Close60.89
ShortableYes LT Debt/Eq0.00 EarningsNov 03 AMC Payout- Avg Volume838.47K Price65.00
Recom1.60 SMA2011.22% SMA5015.91% SMA20075.11% Volume697,354 Change6.75%
Nov-04-22Downgrade RBC Capital Mkts Outperform → Sector Perform $52 → $55
Sep-28-22Upgrade BofA Securities Neutral → Buy
Nov-19-21Initiated JMP Securities Mkt Outperform $77
Jun-18-21Upgrade BofA Securities Underperform → Neutral $12 → $49
Jun-08-21Reiterated Oppenheimer Outperform $45 → $54
May-26-21Initiated Citigroup Buy $39
Feb-26-21Upgrade RBC Capital Mkts Sector Perform → Outperform $14 → $28
Feb-12-21Upgrade Jefferies Hold → Buy $15 → $30
Feb-02-21Upgrade BTIG Research Neutral → Buy $29
Dec-07-20Initiated H.C. Wainwright Buy $22
Show Previous Ratings
Nov-29-22 12:42PM
Nov-22-22 10:07AM
Nov-21-22 04:05PM
Nov-14-22 02:34PM
Nov-09-22 06:07AM
09:11AM Loading…
Nov-07-22 09:11AM
Nov-04-22 11:13AM
Nov-03-22 07:15PM
04:05PM
09:05AM
Oct-27-22 04:05PM
Sep-29-22 09:39AM
Sep-28-22 12:01PM
Sep-07-22 11:30AM
Sep-01-22 04:20PM
04:05PM Loading…
04:05PM
Aug-09-22 10:37AM
Aug-08-22 05:45PM
04:05PM
Aug-07-22 10:27AM
Aug-02-22 04:05PM
Aug-01-22 04:05PM
Jul-01-22 04:16PM
Jun-22-22 10:47AM
Jun-09-22 11:30AM
Jun-02-22 04:05PM
May-08-22 08:02AM
May-06-22 12:24PM
May-05-22 06:35PM
04:05PM
03:44PM Loading…
May-02-22 03:44PM
Apr-28-22 04:05PM
Apr-26-22 08:30AM
Apr-21-22 10:13AM
Mar-29-22 11:44AM
Mar-28-22 08:30AM
Mar-21-22 04:05PM
Mar-16-22 09:20AM
05:30AM
Feb-18-22 10:05AM
Feb-17-22 05:45PM
04:05PM
Feb-10-22 04:05PM
Feb-03-22 05:38PM
03:01PM
02:36PM
Jan-28-22 01:38PM
Jan-27-22 01:38PM
Jan-18-22 02:57PM
Jan-10-22 11:02AM
Dec-23-21 08:09AM
Dec-12-21 03:55PM
Dec-07-21 01:51PM
Dec-03-21 11:58AM
Nov-29-21 04:05PM
Nov-25-21 08:25AM
Nov-22-21 10:38AM
Nov-18-21 08:43AM
Nov-10-21 09:14AM
Nov-05-21 08:59AM
Nov-04-21 08:56PM
04:05PM
11:16AM
Nov-01-21 11:26AM
Oct-28-21 04:05PM
11:40AM
Oct-27-21 03:03PM
Oct-26-21 02:03PM
Oct-23-21 06:08AM
Oct-15-21 09:34AM
Oct-12-21 11:40AM
09:10AM
Oct-11-21 01:06PM
Oct-04-21 11:54AM
Oct-01-21 04:30PM
04:05PM
Sep-23-21 11:40AM
Sep-18-21 09:13AM
Sep-09-21 12:00PM
Sep-03-21 04:05PM
Sep-01-21 04:05PM
11:30AM
Aug-25-21 04:46AM
Aug-11-21 08:02AM
Aug-09-21 01:32AM
Aug-06-21 12:41PM
Aug-05-21 05:25PM
04:05PM
Aug-03-21 11:33AM
09:01AM
Jul-29-21 04:05PM
03:05PM
Jul-26-21 03:27PM
09:00AM
Jul-20-21 04:05PM
Jul-17-21 07:37AM
Jul-16-21 11:40AM
07:18AM
Jul-14-21 03:21PM
Jul-13-21 12:22PM
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Garren HidekiChief Medical OfficerDec 01Option Exercise24.904,00099,6004,000Dec 02 09:30 PM
Ekman LarsChair of the BoardDec 01Option Exercise6.4115,834101,49616,077Dec 02 09:30 PM
Garren HidekiChief Medical OfficerDec 01Sale62.514,000250,0400Dec 02 09:30 PM
Ekman LarsChair of the BoardDec 01Sale61.6015,834975,406243Dec 02 09:30 PM
Malecek Michael JChief Legal OfficerNov 30Option Exercise10.275,00051,3505,000Dec 02 09:30 PM
Malecek Michael JChief Legal OfficerNov 30Sale62.285,000311,3760Dec 02 09:30 PM
Nguyen TranChief Strategy Officer and CFONov 23Option Exercise6.7310,00067,30013,200Nov 25 09:31 PM
Nguyen TranChief Strategy Officer and CFONov 23Sale61.0910,000610,8543,200Nov 25 09:31 PM
Walker Karin LChief Accounting OfficerNov 18Option Exercise15.0410,000150,40010,000Nov 18 09:32 PM
Walker Karin LChief Accounting OfficerNov 18Sale57.0710,000570,7090Nov 18 09:32 PM
Cooke ShaneDirectorNov 10Option Exercise6.415,00032,0505,000Nov 10 09:30 PM
Cooke ShaneDirectorNov 10Sale56.175,000280,8280Nov 10 09:30 PM
COLLIER RICHARD TDirectorNov 07Option Exercise6.415,00032,0506,219Nov 09 09:30 PM
COLLIER RICHARD TDirectorNov 07Sale55.625,000278,0831,219Nov 09 09:30 PM
Garren HidekiChief Medical OfficerNov 01Option Exercise24.904,00099,6004,000Nov 03 09:30 PM
Ekman LarsChair of the BoardNov 01Option Exercise6.4115,833101,49016,076Nov 03 09:31 PM
Garren HidekiChief Medical OfficerNov 01Sale61.894,000247,5750Nov 03 09:30 PM
Ekman LarsChair of the BoardNov 01Sale62.8815,833995,658243Nov 03 09:31 PM
Malecek Michael JChief Legal OfficerOct 27Option Exercise10.2720,000205,40020,000Oct 28 09:30 PM
Malecek Michael JChief Legal OfficerOct 27Sale62.0020,0001,240,0040Oct 28 09:30 PM
Malecek Michael JChief Legal OfficerOct 26Option Exercise10.2765,000667,55065,000Oct 28 09:30 PM
Malecek Michael JChief Legal OfficerOct 26Sale60.3165,0003,920,1470Oct 28 09:30 PM
Walker Karin LChief Accounting OfficerOct 24Option Exercise15.0420,000300,80020,000Oct 26 09:30 PM
Walker Karin LChief Accounting OfficerOct 24Sale57.2320,0001,144,6130Oct 26 09:30 PM
Nguyen TranChief Strategy Officer and CFOOct 19Option Exercise6.7310,00067,30013,200Oct 21 09:30 PM
Nguyen TranChief Strategy Officer and CFOOct 19Sale56.4410,000564,3853,200Oct 21 09:30 PM
Cooke ShaneDirectorOct 10Option Exercise6.415,00032,0505,000Oct 12 09:45 PM
Cooke ShaneDirectorOct 10Sale55.915,000279,5500Oct 12 09:45 PM
COLLIER RICHARD TDirectorOct 05Option Exercise6.415,00032,0506,219Oct 07 09:36 PM
COLLIER RICHARD TDirectorOct 05Sale57.925,000289,6221,219Oct 07 09:36 PM
Ekman LarsChair of the BoardOct 03Option Exercise6.4115,833101,49016,076Oct 05 09:46 PM
Garren HidekiChief Medical OfficerOct 03Option Exercise24.904,00099,6004,000Oct 05 09:46 PM
Ekman LarsChair of the BoardOct 03Sale61.5215,833974,082243Oct 05 09:46 PM
Garren HidekiChief Medical OfficerOct 03Sale60.904,000243,6000Oct 05 09:46 PM
Kinney Gene G.President and CEOSep 28Option Exercise6.4116,412105,20129,205Sep 30 09:31 PM
Ekman LarsChair of the BoardSep 28Option Exercise6.4131,666202,97931,909Sep 30 09:30 PM
Cooke ShaneDirectorSep 28Option Exercise6.4110,00064,10010,000Sep 30 09:31 PM
COLLIER RICHARD TDirectorSep 28Option Exercise6.4125,000160,25026,219Sep 30 09:31 PM
Cooke ShaneDirectorSep 28Sale48.0910,000480,9000Sep 30 09:31 PM
Kinney Gene G.President and CEOSep 28Sale53.3816,412876,00812,793Sep 30 09:31 PM
COLLIER RICHARD TDirectorSep 28Sale48.0925,0001,202,2501,219Sep 30 09:31 PM
Ekman LarsChair of the BoardSep 28Sale48.0931,6661,522,818243Sep 30 09:30 PM
Kinney Gene G.President and CEOSep 21Option Exercise6.412,72017,43515,513Sep 23 09:30 PM
Nguyen TranChief Strategy Officer and CFOSep 21Option Exercise6.7310,00067,30013,200Sep 23 09:30 PM
Kinney Gene G.President and CEOSep 21Sale32.022,72087,09012,793Sep 23 09:30 PM
Nguyen TranChief Strategy Officer and CFOSep 21Sale30.7510,000307,4963,200Sep 23 09:30 PM
Garren HidekiChief Medical OfficerSep 15Option Exercise24.904,00099,6004,000Sep 16 09:32 PM
Garren HidekiChief Medical OfficerSep 15Sale30.004,000120,0000Sep 16 09:32 PM
Nguyen TranChief Strategy Officer and CFOAug 24Option Exercise6.7310,00067,30013,200Aug 26 09:31 PM
Nguyen TranChief Strategy Officer and CFOAug 24Sale30.1710,000301,6723,200Aug 26 09:31 PM
Kinney Gene G.President and CEOAug 17Option Exercise6.412,18113,98014,974Aug 19 09:30 PM
Kinney Gene G.President and CEOAug 17Sale32.032,18169,85512,793Aug 19 09:30 PM
Kinney Gene G.President and CEOAug 12Option Exercise6.4120,284130,02033,077Aug 12 09:30 PM
Kinney Gene G.President and CEOAug 12Sale32.1620,284652,29112,793Aug 12 09:30 PM
Kinney Gene G.President and CEOAug 11Option Exercise6.4113,65087,49626,443Aug 12 09:30 PM
Kinney Gene G.President and CEOAug 11Sale32.1613,650438,93112,793Aug 12 09:30 PM
Kinney Gene G.President and CEOAug 10Option Exercise6.419916,35213,784Aug 12 09:30 PM
Kinney Gene G.President and CEOAug 10Sale32.0199131,72412,793Aug 12 09:30 PM
Kinney Gene G.President and CEOAug 05Option Exercise6.4121,506137,85334,299Aug 05 09:34 PM
Kinney Gene G.President and CEOAug 05Sale32.8321,506706,06312,793Aug 05 09:34 PM
Kinney Gene G.President and CEOAug 04Option Exercise6.4120,954134,31533,747Aug 05 09:34 PM
Kinney Gene G.President and CEOAug 04Sale32.1820,954674,31612,793Aug 05 09:34 PM
Garren HidekiChief Medical OfficerAug 01Option Exercise24.904,00099,6004,000Aug 03 09:39 PM
Garren HidekiChief Medical OfficerAug 01Sale30.524,000122,0800Aug 03 09:39 PM
Kinney Gene G.President and CEOJul 27Option Exercise6.413762,41013,169Jul 29 09:30 PM
Kinney Gene G.President and CEOJul 27Sale32.0037612,03212,793Jul 29 09:30 PM
Nguyen TranChief Strategy Officer and CFOJul 22Option Exercise6.737,32049,26410,520Jul 22 09:37 PM
Nguyen TranChief Strategy Officer and CFOJul 22Sale32.557,320238,2543,200Jul 22 09:37 PM
Nguyen TranChief Strategy Officer and CFOJul 21Option Exercise6.7320,560138,36923,760Jul 22 09:37 PM
Nguyen TranChief Strategy Officer and CFOJul 21Sale32.6420,560671,0943,200Jul 22 09:37 PM
Cooke ShaneDirectorJul 20Option Exercise6.4115,00096,15015,000Jul 22 09:33 PM
Nguyen TranChief Strategy Officer and CFOJul 20Option Exercise6.7342,120283,46845,320Jul 22 09:37 PM
Nguyen TranChief Strategy Officer and CFOJul 20Sale32.4942,1201,368,4413,200Jul 22 09:37 PM
Cooke ShaneDirectorJul 20Sale32.9015,000493,5000Jul 22 09:33 PM
Garren HidekiChief Medical OfficerJul 06Option Exercise24.908,000199,2008,000Jul 08 09:34 PM
Garren HidekiChief Medical OfficerJul 06Sale30.008,000240,0000Jul 08 09:34 PM
EcoR1 Capital, LLC10% OwnerMay 05Buy29.021,062,73630,840,59911,584,280May 09 06:01 AM
EcoR1 Capital, LLC10% OwnerMay 05Sale29.021,062,73630,840,59911,584,280May 09 06:01 AM
Cooke ShaneDirectorApr 11Option Exercise6.415,00032,0505,000Apr 13 09:45 PM
Cooke ShaneDirectorApr 11Sale35.085,000175,3820Apr 13 09:45 PM
COLLIER RICHARD TDirectorApr 05Option Exercise6.415,00032,0506,219Apr 07 09:47 PM
COLLIER RICHARD TDirectorApr 05Sale39.415,000197,0271,219Apr 07 09:47 PM
EcoR1 Capital, LLC10% OwnerJan 12Buy37.50300,00011,250,30011,584,280Jan 12 06:12 PM
Selkoe Dennis J.DirectorJan 03Option Exercise9.235,00046,1507,845Jan 05 09:02 PM
Selkoe Dennis J.DirectorJan 03Sale47.455,000237,2332,845Jan 05 09:02 PM